Dexamethasone Sodium Phosphate
FDA-approved product (ointment, ophthalmic), marketed as Decadron, Dexacen-4, Dexacort and 6 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Acne
- Adrenal gland disease
- Adrenal gland hyperfunction
- Adrenocortical insufficiency
- Allergic conjunctivitis
- Allergic rhinitis
- Ankylosing spondylitis
- Aplastic anemia
- Asthma
- Atopic eczema
- Autoimmune thrombocytopenic purpura
- Brain edema
- Bursitis
- Cancer
- Chorioretinitis
- Choroiditis
- and 66 more
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Corticosteroids for local oral treatment; Corticosteroids; Corticosteroids, moderately potent (group ii); Corticosteroids, moderately potent, other combinations; Corticosteroids, combinations for treatment of acne
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli36.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Dexamethasone Sodium Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm95.6% AI-predicted activityagainst MRSALab records exist50+ registered studies
- TaurursodiolExisting use: Bile acids and derivatives79.6% AI-predicted activityagainst MRSA43 registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome74.5% AI-predicted activityagainst MRSA50+ registered studies
- PlecanatideExisting use: Constipation74.4% AI-predicted activityagainst MRSA15 registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia74.2% AI-predicted activityagainst MRSA50+ registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more72.2% AI-predicted activityagainst MRSA50+ registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma70.6% AI-predicted activityagainst MRSA50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more70.1% AI-predicted activityagainst MRSA50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia70.0% AI-predicted activityagainst MRSA4 registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more70.0% AI-predicted activityagainst MRSA50+ registered studies
- Deoxycholic AcidExisting use: Other dermatologicals69.3% AI-predicted activityagainst MRSA50+ registered studies
- ChenodiolExisting use: Cerebrotendinous xanthomatosis, Inborn errors of metabolism69.2% AI-predicted activityagainst MRSA30 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
NCT00458822 · start 2007-02
Registered record
- Registry ID
- NCT00458822
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- bortezomib; dexamethasone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-02
- Completion
- 2015-03
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMultiple Myeloma and Plasma Cell NeoplasmInterventionbortezomib; dexamethasonePhasePhase 2Registry statusCompletedA Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome
NCT00201643 · start 2003-11
Registered record
- Registry ID
- NCT00201643
- Conditions
- Preterm Delivery
- Interventions
- Betamethasone or Dexamethasone (2nd course of ACS); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2003-11
- Completion
- 2008-02
- Enrolment
- 437
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPreterm DeliveryInterventionBetamethasone or Dexamethasone (2nd course of ACS); PlaceboPhasePhase 4Registry statusCompletedThalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy
NCT00205751 · start 2001-08
Registered record
- Registry ID
- NCT00205751
- Conditions
- Multiple Myeloma
- Interventions
- Thalidomide/Dexamethasone vs Melphalan/Prednisone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2001-08
- Completion
- 2009-10
- Enrolment
- 350
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMultiple MyelomaInterventionThalidomide/Dexamethasone vs Melphalan/PrednisonePhasePhase 2 / Phase 3Registry statusCompletedDexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
NCT00006345 · start 1999-11
Registered record
- Registry ID
- NCT00006345
- Conditions
- Drug/Agent Toxicity by Tissue/Organ; Lymphoma
- Interventions
- denileukin diftitox; dexamethasone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1999-11
- Completion
- 2004-03
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDrug/Agent Toxicity by Tissue/Organ; LymphomaInterventiondenileukin diftitox; dexamethasonePhasePhase 2Registry statusCompletedDose-Dense Therapy in Aggressive Lymphoma
NCT00517894
Registered record
- Registry ID
- NCT00517894
- Conditions
- Lymphoma
- Interventions
- CEOP/IMVP-Dexa chemotherapy
- Study type
- EXPANDED_ACCESS
- Phase
- Not recorded
- Registry status
- No longer available
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLymphomaInterventionCEOP/IMVP-Dexa chemotherapyPhaseNot recordedRegistry statusNo longer available